Parallax Volatility Advisers’s Akebia Therapeutics AKBA Stock Holding History

Parallax Volatility Advisers’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-109,683	Closed	-$39K	–	3032
2022 Q2	$39K	Buy	+109,683	New	+$46K	﹤0.01%	2507
2020 Q3	–	Sell	-6,154	Closed	-$84K	–	3016
2020 Q2	$84K	Buy	+6,154	New	+$63.7K	﹤0.01%	2433
2019 Q2	–	Sell	-13,786	Closed	-$113K	–	2497
2019 Q1	$113K	Buy	+13,786	New	+$94.6K	﹤0.01%	2089
2018 Q1	–	Sell	-6,888	Closed	-$102K	–	2177
2017 Q4	$102K	Buy	+6,888	New	+$114K	﹤0.01%	2786
2017 Q2	–	Sell	-879	Closed	-$8K	–	2174
2017 Q1	$8K	Hold	879	–	–	﹤0.01%	3210
2016 Q4	$9K	Hold	879	–	–	﹤0.01%	2794
2016 Q3	$8K	Sell	879 -4,900	-85%	-$41.6K	﹤0.01%	2690
2016 Q2	$43K	Hold	5,779	–	–	﹤0.01%	2219
2016 Q1	$52K	Sell	5,779 -7,700	-57%	-$62.4K	﹤0.01%	2128
2015 Q4	$174K	Sell	13,479 -29,221	-68%	-$298K	﹤0.01%	1936
2015 Q3	$412K	Buy	+42,700	New	+$392K	﹤0.01%	1602

Other funds holding AKBA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Parallax Volatility Advisers's AKBA Position: Q3 2022 in Review

Parallax Volatility Advisers sold out of Akebia Therapeutics (AKBA) in Q3 2022, closing a stake of 109,683 shares — an estimated $39K sold.

Parallax Volatility Advisers first reported a position in AKBA in Q3 2015 and held it in 11 quarters. The position peaked at $412K in Q3 2015. 90 funds tracked by Wall St. Rank hold AKBA as of Q3 2022.

Parallax Volatility Advisers reported no remaining Akebia Therapeutics position as of Q3 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 109,683 Akebia Therapeutics shares in Q3 2022, an estimated $39K.
Parallax Volatility Advisers first reported a position in Akebia Therapeutics in Q3 2015 and held it in 11 quarters.
Parallax Volatility Advisers's Akebia Therapeutics position peaked at $412K in Q3 2015.
90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2022.

Based on Parallax Volatility Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.